Axsome Therapeutics Inc. shares dipped over 2% on Tuesday — their worst session in nearly two weeks — after the company ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Operator Good morning, and welcome to the Axsome Therapeutics fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Reports Q4 revenue $118.8M, consensus $117.84M. “2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly ...

Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...

The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1 per share. The biopharmaceutical company posted revenue of ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Axsome Therapeutics in a note issued ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110 ...